MNG835
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.455
- KRAS_SIGNALING_DN+0.324
- TNFA_SIGNALING_VIA_NFKB+0.281
- SPERMATOGENESIS+0.255
- G2M_CHECKPOINT+0.180
- KRAS_SIGNALING_UP+0.162
- HEDGEHOG_SIGNALING+0.155
- ESTROGEN_RESPONSE_LATE+0.150
- ANGIOGENESIS+0.141
- COAGULATION+0.141
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.534
- MYC_TARGETS_V2-0.525
- DNA_REPAIR-0.522
- MYC_TARGETS_V1-0.499
- UNFOLDED_PROTEIN_RESPONSE-0.447
- ADIPOGENESIS-0.392
- PROTEIN_SECRETION-0.384
- P53_PATHWAY-0.353
- PI3K_AKT_MTOR_SIGNALING-0.344
- INTERFERON_ALPHA_RESPONSE-0.323
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1516039 | — | — | 0.906 |
| 2 | MNG472 | — | — | 0.895 |
| 3 | SRR6013484 | — | cohortA4 | 0.878 |
| 4 | GSM5359442 | — | — | 0.862 |
| 5 | MNG1139 | — | — | 0.860 |
| 6 | MNG1123 | — | — | 0.857 |
| 7 | MNG1150 | — | — | 0.849 |
| 8 | SRR1516036 | — | — | 0.849 |
| 9 | MNG934 | — | — | 0.848 |
| 10 | MNG874 | — | — | 0.844 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.455 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.324 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.281 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.255 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.180 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.162 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.155 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.150 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.141 | Remibrutinib | — uncovered |
| COAGULATION | 0.141 | Binimetinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.125 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.110 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.103 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.084 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.075 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.068 | Inavolisib | — uncovered |
| MYOGENESIS | 0.043 | Inavolisib | — uncovered |
| HYPOXIA | 0.024 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.007 | Idelalisib | — uncovered |
| COMPLEMENT | 0.002 | Inavolisib | — uncovered |